Pinealon vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
PinealonGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- ~7 days (estimated, long-acting design)
- Admin Route
- SubQ, Oral, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mg (oral) or 50–100 mcg (SC)
- Under investigation in Phase 1/2 trials
- Frequency
- Once daily for 10 days
- Once weekly
- Key Benefits
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —